BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 16861089)

  • 1. A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination.
    Cheng JW
    Clin Ther; 2006 May; 28(5):666-78. PubMed ID: 16861089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure.
    Angus DC; Linde-Zwirble WT; Tam SW; Ghali JK; Sabolinski ML; Villagra VG; Winkelmayer WC; Worcel M;
    Circulation; 2005 Dec; 112(24):3745-53. PubMed ID: 16344404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of nitrates and hydralazine in heart failure: clinical evidence before the african american heart failure trial.
    Elkayam U; Bitar F
    Am J Cardiol; 2005 Oct; 96(7B):37i-43i. PubMed ID: 16226934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients.
    Carmody MS; Anderson JR
    Cardiol Rev; 2007; 15(1):46-53. PubMed ID: 17172884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The African American Heart Failure Trial: a clinical trial update.
    Taylor AL
    Am J Cardiol; 2005 Oct; 96(7B):44-8. PubMed ID: 16226935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.
    Ferdinand KC; Elkayam U; Mancini D; Ofili E; PiƱa I; Anand I; Feldman AM; McNamara D; Leggett C
    Am J Cardiol; 2014 Jul; 114(1):151-9. PubMed ID: 24846808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Ziesche S; Cobb FR; Cohn JN; Johnson G; Tristani F
    Circulation; 1993 Jun; 87(6 Suppl):VI56-64. PubMed ID: 8500241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
    Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
    Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure.
    Ofili E; Anand I; Williams RA; Akinboboye O; Xu L; Puckrein G
    Adv Ther; 2017 Aug; 34(8):1976-1988. PubMed ID: 28707284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
    Ghali JK; Tam SW; Ferdinand KC; Lindenfeld J; Sabolinski ML; Taylor AL; Worcel M; Curry CL; Cohn JN;
    Am J Cardiovasc Drugs; 2007; 7(5):373-80. PubMed ID: 18041162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
    Taylor AL; Ziesche S; Yancy CW; Carson P; Ferdinand K; Taylor M; Adams K; Olukotun AY; Ofili E; Tam SW; Sabolinski ML; Worcel M; Cohn JN;
    Circulation; 2007 Apr; 115(13):1747-53. PubMed ID: 17372175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure.
    Thadani U; Jacob RG
    Drugs Today (Barc); 2008 Dec; 44(12):925-37. PubMed ID: 19198701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failure.
    Franciosa JA
    Expert Opin Pharmacother; 2006 Dec; 7(18):2521-31. PubMed ID: 17150006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Loeb HS; Johnson G; Henrick A; Smith R; Wilson J; Cremo R; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI78-87. PubMed ID: 8500244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.
    Cohn JN; Tam SW; Anand IS; Taylor AL; Sabolinski ML; Worcel M;
    J Card Fail; 2007 Jun; 13(5):331-9. PubMed ID: 17602978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
    Taylor AL; Ziesche S; Yancy C; Carson P; D'Agostino R; Ferdinand K; Taylor M; Adams K; Sabolinski M; Worcel M; Cohn JN;
    N Engl J Med; 2004 Nov; 351(20):2049-57. PubMed ID: 15533851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology.
    Franciosa JA; Taylor AL; Cohn JN; Yancy CW; Ziesche S; Olukotun A; Ofili E; Ferdinand K; Loscalzo J; Worcel M;
    J Card Fail; 2002 Jun; 8(3):128-35. PubMed ID: 12140804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT).
    Carson P; Johnson G; Fletcher R; Cohn J
    J Am Coll Cardiol; 1996 Mar; 27(3):642-9. PubMed ID: 8606276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
    Carson P; Ziesche S; Johnson G; Cohn JN
    J Card Fail; 1999 Sep; 5(3):178-87. PubMed ID: 10496190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group.
    Johnson G; Carson P; Francis GS; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI32-9. PubMed ID: 8500237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.